Brief: Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter
20/07/2021 14:16
July 20 (Reuters) - Mabpharm Ltd 2181.HK :
* SORRENTO ANNOUNCES ITS PARTNER MABPHARM HAS RECEIVED
MARKETING
APPROVAL IN CHINA FOR INFLIXIMAB BIOBETTER
Source text for Eikon: ID:nGNX5ssKnB
Further company coverage: 2181.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mabpharm
See all newsBrief: Mabpharm Says NMPA Approves CMAB807X (Denosumab Injection) NDA
Brief: Mabpharm Says NMPA Approves Cmab807 (Denosumab Injection) NDA
Brief: Mabpharm FY Profit And Total Comprehensive Income Attributable Rmb57.1 Million
Brief: Mabpharm Says Approval From Drug Regulatory Authority Of Pakistan On Registration Of Core Product,CMAB008
Brief: Mabpharm Says Approval From Indonesian National Agency Of Drug And Food Control Of CMAB008